Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

81. Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study Full Text available with Trip Pro

Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find

2017 NIHR HTA programme

82. Preventing drug-related adverse events following hospital discharge: the role of the pharmacist Full Text available with Trip Pro

Preventing drug-related adverse events following hospital discharge: the role of the pharmacist Transition of care (ToC) points, and in particular hospital admission and discharge, can be associated with an increased risk of adverse drug events (ADEs) and other drug-related problems (DRPs). The growing recognition of the pharmacist as an expert in medication management, patient education and communication makes them well placed to intervene. There is evidence to indicate that the inclusion

2017 Integrated pharmacy research & practice

83. Trends in Perioperative Major Adverse Cardiovascular and Cerebrovascular Events associated with Non-Cardiac Surgery Full Text available with Trip Pro

Trends in Perioperative Major Adverse Cardiovascular and Cerebrovascular Events associated with Non-Cardiac Surgery Major adverse cardiovascular and cerebrovascular events (MACCE) are a significant source of perioperative morbidity and mortality following noncardiac surgery.To evaluate national trends in perioperative cardiovascular outcomes and mortality after major noncardiac surgery and to identify surgical subtypes associated with cardiovascular events using a large administrative database (...) occurred in 317 479 hospitalizations (3.0%), corresponding to an annual incidence of approximately 150 000 events after applying sample weights. Major adverse cardiovascular and cerebrovascular events occurred most frequently in patients undergoing vascular (7.7%), thoracic (6.5%), and transplant surgery (6.3%). Between 2004 and 2013, the frequency of MACCE declined from 3.1% to 2.6% (P for trend <.001; adjusted odds ratio [aOR], 0.95; 95% CI, 0.94-0.97) driven by a decline in frequency

2017 JAMA cardiology

84. The effect of endotracheal tubes versus laryngeal mask airways on perioperative respiratory adverse events in infants: a randomised controlled trial. Full Text available with Trip Pro

The effect of endotracheal tubes versus laryngeal mask airways on perioperative respiratory adverse events in infants: a randomised controlled trial. Perioperative respiratory adverse events (PRAE) are the most common critical incidents in paediatric anaesthesia and occur more often in infants. Use of laryngeal mask airways (LMAs) is associated with reduced PRAE compared with endotracheal tubes in older children (>1 year). We aimed to evaluate the effect of these devices on the incidence

2017 Lancet Controlled trial quality: predicted high

85. In adults with ankle osteoarthritis (OA), is total ankle replacement/fusion/debridement better than no treatment for pain and function, risks and harms and adverse events?

In adults with ankle osteoarthritis (OA), is total ankle replacement/fusion/debridement better than no treatment for pain and function, risks and harms and adverse events? Getting Evidence into Clinical Practice: Musculoskeletal Research Facilitation Group (CAT Group) Date: February 2018 CAT Lead: Jo Pike Date CAT completed: February 2018 joannapike@nhs.net Date CAT to be reviewed: February 2021 Specific Question: In adults with ankle Osteoarthritis (OA) A is total ankle replacement/fusion (...) /debridement better than no treatment for pain and function, risks and harms and adverse events? Clinical bottom line At present, there are no studies that compare surgical intervention with no treatment for the management of patients with ankle OA. Due to the lack of evidence of comparing no treatment with surgical intervention for pain and function, risks and harms and adverse events, then clinical practice should remain unchanged. Within the available evidence, it is apparent that surgical intervention

2017 Public Health England

86. Randomised controlled trial: Intensive blood pressure lowering provides no additional benefits and results in more adverse events

Randomised controlled trial: Intensive blood pressure lowering provides no additional benefits and results in more adverse events Intensive blood pressure lowering provides no additional benefits and results in more adverse events | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Intensive blood pressure lowering provides no additional benefits and results in more adverse events Article Text Therapeutics/Prevention Randomised controlled trial

2017 Evidence-Based Medicine

87. Adverse events associated with ERCP

Adverse events associated with ERCP GUIDELINE Adverse events associated with ERCP Prepared by: ASGE STANDARDS OF PRACTICE COMMITTEE Vinay Chandrasekhara, MD, Mouen A. Khashab, MD, V. Raman Muthusamy, MD, FASGE, Ruben D. Acosta, MD, Deepak Agrawal, MD, MPH, David H. Bruining, MD, Mohamad A. Eloubeidi, MD, MHS, FASGE, Robert D. Fanelli, MD, FACS, FASGE, SAGES Representative, Ashley L. Faulx, MD, FASGE, Suryakanth R. Gurudu, MD, FASGE, Shivangi Kothari, MD, Jenifer R. Lightdale, MD, MPH, FASGE (...) consider the clinical appropriateness of ERCP, it is important for them to have a thorough understanding of available alter- natives and of the potential adverse events associated with the procedure. In addition, they must understand and attempt to follow maneuvers that reduce the risk of adverse events. Early recognition and appropriate manage- ment of potential adverse events are critical to reducing morbidity and mortality associated with the procedure. The diagnosis and management of all adverse

2017 American Society for Gastrointestinal Endoscopy

88. Cohort Study: Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder

Cohort Study: Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adverse events associated with mood stabiliser treatment should be continuously monitored

2017 Evidence-Based Medicine

89. In patients with non-operatively (conservatively) managed to tendo-achilles (TA) ruptures, is accelerated rehabilitation superior to routine rehabilitation for reducing pain and return to function time, without increasing adverse events of tendon lengthen

In patients with non-operatively (conservatively) managed to tendo-achilles (TA) ruptures, is accelerated rehabilitation superior to routine rehabilitation for reducing pain and return to function time, without increasing adverse events of tendon lengthen Getting Evidence into Clinical Practice: Musculoskeletal Research Facilitation Group (CAT Group) Date:19.11.2016 CAT Lead: Fraser Philp Date CAT completed: 19.11.2016 Email: f.d.philp@keele.ac.uk Date CAT to be reviewed: 19.11.2018 Specific (...) Question: In patients with non-operatively (conservatively) managed tendo-achilles (TA) ruptures, is accelerated rehabilitation superior to routine rehabilitation for reducing pain and return to function time, without increasing adverse events of tendon lengthening and re-rupture rates? Clinical bottom line In patients with non-operatively (conservatively) managed TA ruptures, there is no evidence that compares an accelerated rehabilitation programme against routine rehabilitation. Within the papers

2017 Public Health England

90. Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. Full Text available with Trip Pro

Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. Concerns have been raised about the safety of surgery for stress urinary incontinence and pelvic organ prolapse using transvaginal mesh. We assessed adverse outcomes after first, single mesh procedures and comparable non-mesh procedures.We did a cohort study of women in Scotland aged 20 years or older

2016 Lancet

91. Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event Full Text available with Trip Pro

Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event 30241172 2019 03 04 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event. 1-4 10.1200/JGO.2016.007765 Adhikari Narayan N All authors: All India Institute of Medical Sciences, New Delhi, Delhi, India. Kumar Pavnesh P All authors: All India Institute of Medical Sciences, New Delhi, Delhi, India. Venkatesulu Bhanu P BP All authors: All India Institute

2016 Journal of global oncology

92. Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events Full Text available with Trip Pro

Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events Anthrax postexposure prophylaxis (PEP) was recommended to 42 people after a laboratory incident that involved potential aerosolization of Bacillus anthracis spores in 2 laboratories at the Centers for Disease Control and Prevention in 2014. At least 31 (74%) individuals who initiated PEP did not complete either the recommended 60 days of antimicrobial therapy or the 3-dose vaccine regimen. Among the 29 (...) that discontinued the antimicrobial component of PEP, most (38%) individuals discontinued PEP because of their low perceived risk of infection; 9 (31%) individuals discontinued prophylaxis due to PEP-related minor adverse events, and 10% cited both low risk and adverse events as their reason for discontinuation. Most minor adverse events reported were gastrointestinal complaints, and none required medical attention. Individuals taking ciprofloxacin were twice as likely (RR = 2.02, 95% CI = 1.1-3.6

2016 Health security

93. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. Full Text available with Trip Pro

US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. The Patient Protection and Affordable Care Act of 2010 brought attention to adverse drug events in national patient safety efforts. Updated, detailed, nationally representative data describing adverse drug events can help focus these efforts.To describe the characteristics of emergency department (ED) visits for adverse drug events in the United States in 2013-2014 and describe changes in ED visits for adverse drug (...) events since 2005-2006.Active, nationally representative, public health surveillance in 58 EDs located in the United States and participating in the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project.Drugs implicated in ED visits.National weighted estimates of ED visits and subsequent hospitalizations for adverse drug events.Based on data from 42 585 cases, an estimated 4.0 (95% CI, 3.1-5.0) ED visits for adverse drug events occurred per 1000

2016 JAMA

94. Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing Full Text available with Trip Pro

Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing 27893112 2016 12 13 2018 12 02 1538-3598 316 20 2016 Nov 22 JAMA JAMA Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing. 2092-2093 10.1001/jama.2016.16392 Kessler Chad C Durham VA Medical Center, Durham, North Carolina. Ward Michael J MJ Vanderbilt University Medical Center, Nashville, Tennessee. McNaughton Candace D CD Vanderbilt University Medical Center, Nashville, Tennessee. eng K23 HL125670 HL (...) NHLBI NIH HHS United States K23 HL127130 HL NHLBI NIH HHS United States Editorial Comment United States JAMA 7501160 0098-7484 AIM IM JAMA. 2016 Nov 22;316(20):2115-2125 27893129 Drug-Related Side Effects and Adverse Reactions Humans Medication Errors Outpatients 2016 11 29 6 0 2016 11 29 6 0 2016 12 15 6 0 ppublish 27893112 2585959 10.1001/jama.2016.16392 PMC5779096 NIHMS934127 Can J Hosp Pharm. 2015 May-Jun;68(3):202-9 26157181 JAMA. 2016 Nov 22;316(20):2115-2125 27893129 J Med Ethics. 2015 Nov;41

2016 JAMA

95. CJEM Infographic: Adverse Events Following Pediatric Catheterization

CJEM Infographic: Adverse Events Following Pediatric Catheterization CJEM Infographic: Adverse Events Following Pediatric Catheterization - CanadiEM CJEM Infographic: Adverse Events Following Pediatric Catheterization In , by Simon Huang November 18, 2016 This month CanadiEM is featuring an article from the Canadian Journal of Emergency Medicine (CJEM) that focuses on the use of pediatric catheterization in the emergency department (ED). Currently, catheterization is used in the pediatric ED (...) for diagnosing young children with a suspected urinary tract infection (UTI). However, there have been few studies that have looked at short-term adverse events in this population. As shown in this CanadiEM infographic, this study by Ouellet-Pelletier et al . 1 set out to assess adverse events in the week following diagnostic urinary catheterization in children in the pediatric ED. Specifically, a prospective observational study was performed in a single ED at Sainte-Justine University Hospital. Parents

2016 CandiEM

96. Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews. Full Text available with Trip Pro

Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews. The prevalence of knee osteoarthritis (OA)/degenerative joint disease (DJD) is increasing in the USA. Systematic reviews of treatment efficacy and adverse events (AEs) of hyaluronic acid (HA) injections report conflicting evidence about the balance of benefits and harms. We review evidence on efficacy and AEs of intraarticular (...) : pooled analysis of ten placebo-controlled, blinded trials showed a standardized mean difference of -0.23 (95 % confidence interval (CI) -0.45 to -0.01) favoring HA at 6 months. Studies reported few serious adverse events (SAEs) and no significant differences in non-serious adverse events (NSAEs) (relative risk (RR) [95 % CI] 1.03 [0.93-1.15] or SAEs (RR [95 % CI] 1.39 [0.78-2.47]). A recent prior systematic review reported similar functional outcomes, but significant SAE risk. Differences in SAE

2016 Systematic Reviews

97. Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data Full Text available with Trip Pro

Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data Understanding adverse event patterns in clinical studies across populations is important for patient safety and protection in clinical trials as well as for developing appropriate drug therapies, procedures, and treatment plans.The objective of our study was to conduct a data-driven population-based analysis to estimate the incidence, diversity, and association patterns of adverse events by age (...) of the clinical trials patients and participants.Two aspects of adverse event patterns were measured: (1) the adverse event incidence rate in each of the patient age groups and (2) the diversity of adverse events defined as distinct types of adverse events categorized by organ system. Statistical analysis was done on the summarized clinical trial data. The incident rate and diversity level in each of the age groups were compared with the lowest group (reference group) using t tests. Cohort data was obtained

2016 JMIR medical informatics

98. Diagnostic Accuracy of High-Sensitivity Cardiac Troponin T at Presentation Combined With History and ECG for Ruling Out Major Adverse Cardiac Events (Abstract)

Diagnostic Accuracy of High-Sensitivity Cardiac Troponin T at Presentation Combined With History and ECG for Ruling Out Major Adverse Cardiac Events We evaluate the diagnostic accuracy of a high-sensitivity cardiac troponin T (hs-cTnT) level less than 5 ng/L or less than or equal to 14 ng/L at emergency department (ED) presentation, combined with the emergency physician's assessment of history and ECG, for ruling out major adverse cardiac events within 30 days.This prospective observational (...) study enrolled consecutive ED chest pain patients. Emergency physicians' assessments of patient history and ECG were collected. The primary outcome was 30-day major adverse cardiac events, defined as acute myocardial infarction, unstable angina, cardiogenic shock, ventricular arrhythmia, atrioventricular block, cardiac arrest, or death of cardiac or unknown cause.A total of 1,138 patients were included in the final analysis. The combination of hs-cTnT less than 5 ng/L, a nonischemic ECG result

2016 EvidenceUpdates

99. Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting (Abstract)

Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting Management of antithrombotic therapy in patients with atrial fibrillation (AF) and coronary stenting remains challenging, and there is a need for efficient tools to predict their risk of different types of cardiovascular events and death. Several scores exist such as the CHA2DS2-VASc score (...) , the Global Registry of Acute Coronary Events (GRACE) score, the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score, the Anatomical and Clinical Syntax II Score and the Reduction of Atherothrombosis for Continued Health score. These 5 scores were investigated in patients with AF with coronary stenting with the aim of determining which was most predictive for stroke/thromboembolic (TE) events, nonlethal coronary events, all-cause mortality, and major adverse

2016 EvidenceUpdates

100. Induction of labour with retrievable prostaglandin vaginal inserts: outcomes following retrieval due to an intrapartum adverse event Full Text available with Trip Pro

Induction of labour with retrievable prostaglandin vaginal inserts: outcomes following retrieval due to an intrapartum adverse event To assess adverse event (AE) resolution, delivery mode and neonatal outcomes after misoprostol or dinoprostone vaginal insert (MVI or DVI) retrieval due to AE during induction of labour (IOL).Randomised, double-blind trial, EXPEDITE.Thirty five obstetric departments, USA.Consisted of 1358 pregnant women with modified Bishop score ≤4 eligible for pharmacological (...) and DVI, respectively (P = 0.440).AEs leading to insert retrieval were primarily uterine tachysystole with FHR involvement and category II/III FHR patterns. Insert retrieval due to an AE did not prolong time to delivery for either prostaglandin insert.Induction with prostaglandin vaginal inserts: outcomes following retrieval due to intrapartum adverse event.© 2016 Ferring Pharmaceuticals. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal

2016 EvidenceUpdates Controlled trial quality: predicted high